tiprankstipranks
Advertisement
Advertisement

GYRE Stock Latest News

Gyre Therapeutics Strengthens Board with New Director Appointments
Company AnnouncementsGyre Therapeutics Strengthens Board with New Director Appointments
18d ago
8K
GYRE
Gyre Therapeutics files to sell 30.22M shares of common stock for holders
PremiumThe Fly
Gyre Therapeutics files to sell 30.22M shares of common stock for holders
1M ago
GYRE
Gyre Therapeutics Shareholders Approve Directors and Governance Measures
PremiumCompany Announcements
Gyre Therapeutics Shareholders Approve Directors and Governance Measures
2M ago
8K
GYRE
Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy
PremiumCompany Announcements
Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy
2M ago
8K
GYRE
Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion
PremiumCompany Announcements
Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion
3M ago
8K
GYRE
Gyre Therapeutics’ F351 NDA Accepted for Priority Review
PremiumCompany AnnouncementsGyre Therapeutics’ F351 NDA Accepted for Priority Review
3M ago
8K
GYRE
Gyre Therapeutics announces China NMPA acceptance of F351 NDA
Premium
The Fly
Gyre Therapeutics announces China NMPA acceptance of F351 NDA
3M ago
GYRE
Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year
Premium
The Fly
Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year
3M ago
GYRE
GYRE Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
GYRE Upcoming Earnings Report: What to Expect?
3M ago
GYRE
Gyre Therapeutics Completes Cullgen Acquisition and Leadership Transition
PremiumCompany Announcements
Gyre Therapeutics Completes Cullgen Acquisition and Leadership Transition
3M ago
8K
GYRE
Gyre Therapeutics Files NDA in China for F351
PremiumCompany Announcements
Gyre Therapeutics Files NDA in China for F351
4M ago
8K
GYRE
Buy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval
PremiumRatings
Buy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval
5M ago
GYRE
Gyre Therapeutics’ liver fibrosis candidate granted priority review in China
PremiumThe FlyGyre Therapeutics’ liver fibrosis candidate granted priority review in China
5M ago
GYRE
Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions
Premium
Company Announcements
Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions
5M ago
GYRE
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs
Premium
Company Announcements
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs
5M ago
8K
GYRE
Gyre Therapeutics reports Q4 EPS (2c), consensus 1c
PremiumThe Fly
Gyre Therapeutics reports Q4 EPS (2c), consensus 1c
5M ago
GYRE
Gyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M
PremiumThe Fly
Gyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M
5M ago
GYRE
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger
PremiumCompany Announcements
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger
5M ago
8K
GYRE
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
PremiumThe Fly
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
5M ago
GYRE
PULM
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
PremiumThe FlyGyre Therapeutics to acquire Cullgen in $300M all-stock transaction
5M ago
GYRE
PULM
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
Premium
The Fly
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
5M ago
GYRE
PULM
Regulatory De-Risking and Priority Review for Hydronidone Underscore Upside in Gyre Therapeutics Shares
Premium
Ratings
Regulatory De-Risking and Priority Review for Hydronidone Underscore Upside in Gyre Therapeutics Shares
7M ago
GYRE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >